3 days ago
Cerus Corporation to Participate in the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time.
A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
